Company Profile
REYON Pharmaceutical manufactures and sells medicines. The company offers its products under the areas of adrenal corticosteroides. Its portfolio also includes angiotensin II receptor antagonists, antibiotics, anticholinergics, antiemetic, antihypertensives, anti-inflammatory enzymes, antilipidemic, antirheumatic, and oral hypoglycemic agents, anti-peptic ulcer, antispasmodics, benign prostatic hypertrophy, cough and cold remedies, cardiac stimulant, genitourinary smooth muscle relaxants, hemostatics, immunosuppressants, rheumatoid arthritis, local anesthetics, migraine drugs, miscellaneous cardiovascular system drugs, neuromuscular disorder related drugs, nootropics and neurotonics, NSAIDs, respiratory stimulants, skeletal muscle relaxants, and vasodilators.
It also develops VM202RY, a vascular neurological disease, etc. gene therapy drug, which is in Phase II clinical trial to treat coronary artery disease, chronic non-healing diabetic/ischemic ulcers, diabetic neuropathy, and amyotrophic lateral sclerosis.
Its portfolio also includes VM206RY, anti-cancer gene therapy, which is under Phase I clinical trials for treatment of breast cancer, RY103 [NS101], therapeutics antibody for Alzheimer, RY104, a gene therapy to treat age-related macular degeneration
BIO-101, a HBV gene vaccine, which is in preclinical studies for hepatitis B, RY105, gene therapy to treat liver fibrosis, GB102, for treatment of chronic kidney and coronary artery disease, RY110 which is an iPSC-derived NK cell therapy for solid tumors, and RY108, an antifungal drug which is under preclinical study.
Additionally, it engages in the research of RY106/RY107, a mRNA-based virus vaccine and gene therapy for anti-virus and rare genetic diseases RY109 which is a pDNA-based cancer vaccine for treatment of Ovarian cancer. Founded in 1955, REYON Pharmaceutical is headquartered in Seoul, South Korea.